Onco-primary Care Networking to Support TEAM-based Care

  • STATUS
    Recruiting
  • End date
    Mar 31, 2024
  • participants needed
    800
  • sponsor
    Duke University
Updated on 4 October 2021
diabetes
cardiovascular disease
cancer surgery
cancer
hypertension
chronic disease
type 2 diabetes mellitus
lung cancer
treatment regimen
primary cancer
solid tumor
hypercholesterolemia
a 12
cancer care
dyslipidemia
cardiovascular complications
lung carcinoma

Summary

The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a dynamic treatment regimen approach. The investigators propose to randomize 800 adults with newly-diagnosed selected cancers treated with curative intent (breast, prostate, colorectal, endometrial, non-small cell lung, and endometrial) and with >1 selected cardiovascular disease (CVD) comorbidity (hypertension, type 2 diabetes mellitus, hypercholesterolemia). Participants will be enrolled through Duke Cancer Institute and two community-based oncology practices, both settings serving socio-demographically diverse populations. The unit of randomization will be the PCP clinic; there will be ~80 PCP clinics across North Carolina involved in the study. The overarching goals of this study are to improve chronic disease management and communication among cancer survivors by engaging PCPs as active members of the cancer care team and reframing the message to cancer survivors and providers.

A diversity supplement with retrospective and qualitative components has been added to abstract older adults with solid tumors who underwent cancer surgery at DUHS. Aims include (1) to estimate the prevalence of cardiovascular complications 90 postoperative days among older adults with solid tumors undergoing surgery, and its association with care coordination between surgical providers and PCPs ; (2) to develop a risk index for cardiovascular complications 90 days of surgery among older adult patients with a solid tumor; and (3) to Assess experience and perceptions of PCPs on care coordination with surgical providers of older adults with a solid tumor following cancer surgery.

Description

This is an 18-month cluster randomized controlled trial using a SMART design with two randomizations (the second using an embedded dynamic treatment regimen), with a target enrollment of 800 patients with one of six solid tumors (stage I-III breast, prostate, colorectal, endometrial, and head/neck cancer; stage I-II non-small cell lung cancer) who are being treated with curative intent. To engage the PCP early in the process, the investigators will enroll patients at one of their first visits with a cancer specialist (e.g., surgeon, radiation or medical oncologist). The investigators estimate that 80 unique community-based PCP clinics across North Carolina will be involved in the study. The investigators will determine the effectiveness of the multi-level intervention compared with usual care on (1) Healthcare Effectiveness Data and Information Set (HEDIS) quality measures of management of the three CVD comorbidities using laboratory testing (glycated hemoglobin [A1c], lipid profile) and blood pressure measurements; (2) medication adherence assessed pharmacy refill data using Proportion of Days Covered (PDC); and (3) patient-provider communication (Patient-Centered Communication in Cancer Care, PCC-Ca-36).

Key aspects of the intervention are to: reframe the message to patients, PCPs, oncologists, and the respective health care teams in these two settings to emphasize the importance of optimizing the management of comorbidities during and after cancer therapy; promote a change in the workflow in both PCP and oncology practices; enhance PCP-oncologist relationships, and utilize EHR technology. There are two phases of the intervention, both having patient- and PCP-level components. During the first phase of the intervention, occurring with the first randomization, the investigators will test the effectiveness of a self-guided, informational strategy (iGuide). For PCP clinics that do not achieve the HEDIS targets, a booster phase with tailored (patient-level) and targeted (PCP-level) strategies will be tested with a second randomization (iGuide2).

The intervention has been designed to leverage communication tools with in our electronic health record (EHR), Epic . For patients who agree to receive study communications through Epic's patient portal, MyChart, we created an automated messaging system using a dynamic, rules-based protocol which determines the proper language to send each subject based on their study arm and time since enrollment. We developed a similar rules-based automated messaging system for provider communications. This method sends letters to a provider's Epic inbox, called InBasket, for Duke providers and PCPs in the community who have limited access to the Duke EMR through a portal called MedLink. Epic will send letters to PCPs outside of Duke who do not have MedLink access by fax. These outside providers will also be given the opportunity to enroll in MedLink if they are interested.

All participants in the study will be given a survivorship care plan based on the American Society of Clinical Oncology (ASCO) template. Because the investigators will be recruiting participants at our cancer centers and community practices, there will be an inevitable contamination across cancer specialists. Thus, the investigators did not include an oncology-level intervention. However, cancer specialists are integral to the patient- and PCP-level interventions. At the end of the study, patients and PCPs will be mailed a newsletter with a summary of the study findings. Lastly, it is inevitable that some patients will change their PCP during the study. When notified of the change, the research team will send the new PCP the intervention materials.

Supplement

A retrospective data analysis of Duke cancer registry data integrated with EHR data elements linked by the medical record number will done. The study cohort will consist of older adults 65 years who have 1 cardiovascular comorbidity (hypertension, type 2 diabetes, dyslipidemia) and underwent cancer surgery for solid tumors at DUHS from January 1st, 2017 to December 31st 2019. Cancers of interest are breast, prostate, colorectal, endometrial, gastric, esophageal, liver, pancreatic, renal cell, bladder, ovarian, head/neck, and non-small cell lung cancer. Cancer diagnoses will be grouped according to the International Classification of Diseases for Oncology, 3rd revision (ICD-O-3). Key variables to be abstracted include demographic, clinical (comorbidities & pertinent history, medications, cancer treatment, labs), geriatric-specific (frailty, function, cognition, operative, post-operative, and PCP follow-up data.

The qualitative component will involve semi-structured interviews with PCPs of older adults with solid tumors who underwent cancer surgery within a 12-month period in the DUHS. Participating PCPs will complete an audio-recorded semi-structured interview that will last approximately 30 minutes. Qualitative interview: We will design a semi-structured interview guide assessing perspectives on (1) frequency, modes, and perceived quality of communication with surgical providers during transitions in care from surgery (2) perceived barriers to effective care coordination with surgical providers (3) how communication and care coordination can be improved. Open-ended prompts may include "Please describe your experience with care coordination with surgical providers of older adults undergoing cancer surgery?" "What challenges have you faced when communicating with surgical providers of your older adult patients?"; "What are your thoughts on ways to improve communication and care coordination after an older adult with solid tumor undergoes surgery?", "Please give examples of particularly good or poor care coordination with surgical providers?" The interview guide will be designed with assistance from the experienced research staff in the Duke Behavioral Health and Survey Research Core.

Details
Condition Malignant neoplasm of prostate, Pancreatic Cancer, Non-Small Cell Lung Cancer, Hypercholesterolemia, NIDDM, Diabetes Mellitus, Colorectal Cancer, Endometrial Carcinoma, Cancer, Pancreatic disorder, Vascular Diseases, Breast Cancer, LIVER DISEASE, Hypertension, Esophageal Diseases, Esophageal Cancer, Blood Pressure, Blood pressure, Renal Cell Carcinoma, HEPATIC NEOPLASM, Neoplasm of unspecified nature of digestive system, Hyperlipidemia, head and neck cancer, Esophageal Carcinoma, Cancer Ovaries, Elevated Blood Pressure, High Cholesterol, Biliary Tract Cancer, Diabetes, prostate carcinoma, type 2 diabetes mellitus, primary cancer, primary malignant neoplasm, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, malignancy, cancers, malignancies, malignant tumor, malignant tumors, esophagus cancer, oesophageal cancer, cancer, liver, cancer, hepatic, cancer, hepatocellular, liver cancers, nsclc, cancer of the head and neck, high blood pressure, arterial hypertension, cancer of the pancreas, diabetes mellitus (dm), prostate cancers, pancreatic cancers, cancer, pancreatic, elevated cholesterol, hypercholesteremia, cancer of the esophagus, oesophageal carcinoma, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2, CVD - Cardiovascular Disease, CVD - Cardiovascular Disease, CVD - Cardiovascular Disease
Treatment Control, iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted)
Clinical Study IdentifierNCT04258813
SponsorDuke University
Last Modified on4 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

A total of 800 individuals who fall under the following criteria will be
enrolled
Diagnosed with any of the following selected solid tumors -
Stage I-III breast [female], colorectal, endometrial, head/neck [H/N], and prostate cancer
Stage I-II non-small cell lung cancer [NSCLC]
Treated with curative intent
-79 years old
Has at least one of three CVD comorbidities (hypertension, diabetes, or hypercholesterolemia) - based upon whether the patient is currently on a medication for the comorbidity at time of recruitment
Had a visit with their PCP in the previous 12 months
Supplement
A sample size of 2800-3000 patients will be pulled from the Duke Cancer
Registry. The retrospective cohort will consist of older adults 65 years who
have 1 CVD comorbidity (hypertension, type 2 diabetes, dyslipidemia) and
underwent cancer surgery for solid tumors (breast, prostate, colorectal
endometrial, gastric, esophageal, liver, pancreatic, renal cell, bladder
ovarian, head/neck, and non-small cell lung cancer) at DUHS from January 1st
to December 31st 2019
The qualitative component of the supplement will involve 12-20 PCPs who are
participating in the ONE TEAM Study. Eligible PCP participants will be
English-speaking providers who have provided care to 1 older adult patient who
has undergone cancer surgery within a 12-month period at DUHS

Exclusion Criteria

Individuals with a history of the following conditions will be ineligible
Myocardial infarction in the previous 24 months
Stage III-IV heart failure (EF <30%)
Stage IV-V chronic kidney disease (eGFR <30)
Participants who progress to metastatic disease during the course of the
-month study period will be allowed to continue to participate unless they
voluntarily withdraw from the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note